| DB ID | MyCo_3770 |
| Title | Diagnosis and Outcomes of Fungal Co-Infections in COVID-19 Infections: A Retrospective Study |
| Year | 2023 |
| PMID | 37764170 |
| Fungal Diseases involved | Fungal infection |
| Associated Medical Condition | COVID-19 |
| Genus | Cryptococcus |
| Species | spp. |
| Organism | Cryptococcus spp. |
| Ethical Statement | The study was conducted in accordance with the Declaration of Helsinki and approved by the In-stitutional Review Board of Creighton University on 18 October 2021 (IRB #2002584). |
| Site of Infection | None |
| Opportunistic invasive | None |
| Sample type | Body fluid |
| Sample source | Bronchoalveolar lavage fluid (BALF) |
| Host Group | Human |
| Host Common name | Human |
| Host Scientific name | Homo sapiens |
| Biomarker Name | GM |
| Biomarker Full Name | Galactomannan |
| Biomarker Type | Diagnostic |
| Biomolecule | Protein |
| Geographical Location | USA |
| Cohort | A total of 177 patients were identified as having a positive COVID-19 diagnosis and use of antifungal therapy during their hospitalization. Four patients were identified as having fungal infections prior to hospitalization for COVID and were thus excluded, resulting in 173 patients in the study. |
| Cohort No. | 173 |
| Age Group | None |
| P Value | None |
| Sensitivity | None |
| Specificity | None |
| Positive Predictive Value | None |
| MIC | None |
| Fold Change | None |
| Pathway | None |
| Disease Introduction Mechanism | None |
| Technique | Assay |
| Analysis Method | GM Assay |
| ELISA kits | None |
| Assay Data | FDA- Fungitell®, Cape Cod International, Inc.; Falmounth, MA, USA |
| Validation Techniques used | FDA Approved-Fungitell assay, GM Assay |
| Up Regulation Down Regulation | Positive |
| Sequence Data | None |
| External Link | None |
